Akeso Biomedical is developing targeted antimicrobial therapies to combat bacterial infections that are resistant to existing treatments. The company focuses on creating novel compounds that enhance efficacy and reduce treatment duration, addressing the growing global health threat of antibiotic resistance.

BiologicsMD provides a cloud‑based platform that centralizes experimental, manufacturing, and regulatory data for biologics development, creating a unified workspace for scientists, engineers, and compliance teams. The system offers automated workflows, predictive analytics, and role‑based security with audit trails, while integrating via APIs with existing LIMS, ERP, and ELN solutions to streamline collaboration and support FDA 21 CFR Part 11 compliance.

The CVAC System is a vacuum-assisted retrieval device that utilizes laser lithotripsy, microjet irrigation, and dynamic aspiration to efficiently remove kidney stone fragments in a single insertion. The SURE Procedure, performed exclusively with this system, achieves superior stone clearance rates compared to standard ureteroscopy, enhancing patient outcomes in kidney stone treatment.

Cellia Science, Inc. develops label-free technology for point-of-care hematology, enabling rapid and accurate blood cell assays, including 5-part white blood cell differentials and platelet counts. This technology reduces result turnaround time from hours or days to minutes, facilitating timely clinical decision-making.

Enhance Diagnostics develops an at-home breath test platform for quantitative, non-invasive monitoring of metabolic waste products. This technology correlates breath ammonia levels with blood urea nitrogen (BUN) in Chronic Kidney Disease (CKD) patients and blood ammonia in Urea Cycle Disorder (UCD) patients. The solution enables real-time patient data collection outside the clinic, improving management for individuals with CKD and UCDs without requiring blood draws.

Filtravate develops ultrafiltration membranes tailored for bioprocessing and biopharmaceutical applications, enabling the precise separation of biomolecules from contaminants. This technology improves product purity and yield while decreasing processing times and costs in biologics production.

i-Seq Biotechnology, Inc. utilizes CRISPR interference screening (CRISPRi-Seq) to identify new vaccine antigens and therapeutic targets for infectious diseases. The company addresses the limitations of existing narrow-spectrum vaccines and the challenges posed by antibiotic resistance in treating infections.

Neurexis Therapeutics is developing tatCN19o, an FDA-approved neuroprotective peptide designed for intravenous administration within four hours of ischemic events such as stroke and cardiac arrest. This therapy aims to significantly reduce neuronal death and cognitive impairment, addressing the substantial healthcare costs and quality of life issues associated with these conditions.

Nob Hill Therapeutics is commercializing the first dry-powder nebulizer designed for high-dose lung delivery to treat severe respiratory diseases. This technology addresses the limitations of current inhalation therapies, enabling more effective medication administration for patients with conditions that are difficult to manage.

Solaris Vaccines develops novel vaccine candidates to address emerging global health threats. The company utilizes the SolaVAX™ method, which employs riboflavin and UV light to inactivate pathogens like viruses, bacteria, and parasites. This approach aims to create vaccines that are faster to produce, safer, and require less complex storage than current methods.

The startup has developed a medical device that utilizes alternating magnetic fields generated by external coils to eliminate biofilm from the surfaces of infected metallic implants. This non-invasive treatment addresses complications associated with surgeries such as knee and hip replacements, as well as trauma-related implants like plates and rods.

Tesseract Structural Innovations has developed the Uniform Deceleration Unit, a lightweight aluminum composite foam technology that enhances passive structural safety in vehicles. This technology specifically addresses the high incidence of serious injuries from offset crashes, contributing to safer automotive designs.

The startup develops miniature gas chromatography systems utilizing microelectromechanical systems (MEMS) technology, featuring microfabricated chips for multi-channel separations. This technology enables businesses to analyze volatile compounds with reduced instrument size and faster results, addressing the need for portable and efficient analytical solutions.